Farmak, a leader in the domestic pharmaceutical market, issued Consolidated Financial Statements for the year 2013, prepared in accordance with the International Financial Reporting Standards (IFRS together with the auditor’s report of PJSC Deloitte and Touche Ukrainian Services Company. The Company promotes such practice for the second consecutive year, however, since 2014 the Company offers a new web page containing key performance indicators to be updated on annual basis.
According to the consolidated financial statements, in 2013 the revenue amounted to UAH 1,948 million, showing an increase of 15% as compared to the revenue in 2012 (UAH 1,692 million). The EBITDA for 2013 was UAH 539 million, which by 17% exceeds that in 2012.
According to the financial statements, in 2013 Farmak confirmed its leading position on the pharmaceutical market, having increased the market share of Ukraine up to 5.1% among all manufacturers of the medicinal products and reached 14.2% of the Ukrainian market of the medicinal products among domestic manufacturers. The Company’s exports amounted to 17.5% (over 20 destinations), with an increase of 23% as compared to that in 2012.
